Biological systems underlying disease are very complex, and targeting a single receptor or signal pathway through monotherapy rarely delivers maximal benefit. Cancer immunotherapy studies have shown that combining two certain antibodies can yield much improved efficacies when compared to single-agent therapy.

At Sound Biologics, we are developing technologies that enable multi-pathway intervention within a single therapeutic product, with the goal of simplifying treatment while expanding therapeutic potentials.